EUS RFA for Treatment of Pancreatic Ductal Adenocarcinoma (PDAC)

• Status: Not yet recruiting
• Trial end date: 2026-03-01
• Target enrollment: 0
• Participant gender: All

Summary

This is a single arm study in the treatment of pancreatic ductal adenocarcinoma (PDAC). The investigators propose to test the tolerability of chemotherapy plus endoscopic ultrasound-guided radiofrequency ablation (EUS-RFA) using the RF Electrode in patients receiving palliative second or third line therapy for unresectable non-metastatic pancreatic cancer.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: NYU Langone Health
• Collaborator: Taewoong Medical

Criteria

Inclusion Criteria:

• Diagnosed and histologically confirmed PDAC by biopsy

• Axial CT scan or MRI consistent with PDAC with at least 1 cm in greatest diameter

• ECOG performance status 0-2

• Patients with locally advanced PDAC, who have not responded or progressed on first line chemotherapy, are deemed not resectable based on multidisciplinary review, and show no evidence of distant metastasis

• Lesions between 1 - 4cm in size

Exclusion Criteria:

• Patients that show evidence of distant metastasis

• Endoscopically non-accessible mass

• Pregnant patients

• Inability to provide informed consent

• Lesions <1cm, or >4cm in greatest diameter